BRPI0816331A2 - Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto. - Google Patents

Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto.

Info

Publication number
BRPI0816331A2
BRPI0816331A2 BRPI0816331A BRPI0816331A2 BR PI0816331 A2 BRPI0816331 A2 BR PI0816331A2 BR PI0816331 A BRPI0816331 A BR PI0816331A BR PI0816331 A2 BRPI0816331 A2 BR PI0816331A2
Authority
BR
Brazil
Prior art keywords
compound
preparing
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
Other languages
English (en)
Portuguese (pt)
Inventor
Yun-Xing Cheng
Xuehong Luo
Vijayaratnam Santhakumar
Miroslaw Jerzy Tomaszewski
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0816331A2 publication Critical patent/BRPI0816331A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
BRPI0816331 2007-09-11 2008-09-09 Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto. BRPI0816331A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97128807P 2007-09-11 2007-09-11
PCT/GB2008/050802 WO2009034380A1 (en) 2007-09-11 2008-09-09 Piperidine derivatives as agonists of muscarinic receptors

Publications (1)

Publication Number Publication Date
BRPI0816331A2 true BRPI0816331A2 (pt) 2015-04-14

Family

ID=40011174

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0816331 BRPI0816331A2 (pt) 2007-09-11 2008-09-09 Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto.

Country Status (18)

Country Link
US (1) US8119661B2 (enExample)
EP (1) EP2197843B1 (enExample)
JP (1) JP2010539151A (enExample)
KR (1) KR20100052528A (enExample)
CN (1) CN101874020B (enExample)
AR (1) AR071245A1 (enExample)
AT (1) ATE539056T1 (enExample)
AU (1) AU2008299604A1 (enExample)
BR (1) BRPI0816331A2 (enExample)
CA (1) CA2699286A1 (enExample)
CL (1) CL2008002689A1 (enExample)
ES (1) ES2377772T3 (enExample)
MX (1) MX2010002584A (enExample)
PE (1) PE20091090A1 (enExample)
RU (1) RU2010110036A (enExample)
TW (1) TW200924766A (enExample)
UY (1) UY31334A1 (enExample)
WO (1) WO2009034380A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813018A (en) * 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
TW200815405A (en) * 2006-06-09 2008-04-01 Astrazeneca Ab Novel compounds
US20090221642A1 (en) * 2008-03-03 2009-09-03 Astrazeneca Ab Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof-176
US20090275574A1 (en) * 2008-05-05 2009-11-05 Astrazeneca Ab Novel compounds-300
AU2012338581B2 (en) 2011-11-18 2016-12-08 Nxera Pharma Uk Limited Muscarinic M1 receptor agonists
CN104640851B (zh) 2012-09-18 2017-05-31 赫普泰雅治疗有限公司 作为毒蕈碱的m1受体激动剂的二环氮杂化合物
JP6478923B2 (ja) 2013-02-07 2019-03-06 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ４受容体アゴニストとしてのピペリジン−１−イル及びアゼピン−１−イルカルボキシレート
GB2519470A (en) * 2013-09-18 2015-04-22 Heptares Therapeutics Ltd Bicyclic aza compounds as muscarinic M1 receptor agonists
HRP20241145T1 (hr) * 2014-02-06 2024-11-22 Nxera Pharma Uk Limited Biciklički aza spojevi kao agonisti muskarinskih receptora
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3066434D1 (en) 1979-11-21 1984-03-08 Kyowa Hakko Kogyo Kk Novel piperidine derivatives, method for the preparation thereof and pharmaceutical compositions containing them
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
JPH09500134A (ja) 1993-07-16 1997-01-07 メルク エンド カンパニー インコーポレーテッド ベンゾオキサジノンおよびベンゾピリミジノンピペリジニル早産防止オキシトシン受容体拮抗剤
EP0786997A4 (en) 1994-10-27 1998-03-11 Merck & Co Inc MUSCARINE ANTAGONISTS
US5756508A (en) 1995-10-31 1998-05-26 Merck & Co., Inc. Muscarine antagonists
WO1997016192A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine antagonists
US5756497A (en) 1996-03-01 1998-05-26 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
ES2314305T3 (es) 1996-09-10 2009-03-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Aminoacidos modificados, medicamentos que contienen estos compuestos y procedimiento para su obtencion.
JPH10158192A (ja) 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
SE9704546D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
WO1999032481A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
BR9907104A (pt) 1998-01-19 2000-10-24 Pfizer Compostos de 4-(2-ceto-1-benzimidazolinil)piperidina como agonistas do receptor orl1
MA26659A1 (fr) 1998-08-06 2004-12-20 Pfizer Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
JP2000323278A (ja) 1999-05-14 2000-11-24 Toray Ind Inc 発光素子
EP1221443B1 (en) 1999-10-13 2004-09-01 Banyu Pharmaceutical Co., Ltd. Substituted imidazolidinone derivatives
SE9904652D0 (sv) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
ES2261463T3 (es) 2000-08-14 2006-11-16 Ortho-Mcneil Pharmaceutical, Inc. Pirazoles sustituidos.
JP2002302675A (ja) 2001-04-06 2002-10-18 Fuji Photo Film Co Ltd 液晶組成物、それを用いた液晶素子およびアゾ化合物
AU2002307416B2 (en) 2001-04-18 2005-08-11 Euro-Celtique S.A. Nociceptin analogs
AU2002338424B2 (en) * 2001-04-18 2005-04-21 Euro-Celtique S.A. Benzimidazolone compounds
EP1386920A4 (en) 2001-04-20 2005-09-14 Banyu Pharma Co Ltd benzimidazolone derivatives
AR036366A1 (es) * 2001-08-29 2004-09-01 Schering Corp Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
WO2003037890A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
WO2003088967A1 (en) 2002-04-18 2003-10-30 Schering Corporation (1-4-piperidinyl) benzimidazole derivatives useful as histamine h3 antagonists
EP1515722A4 (en) 2002-06-17 2006-06-21 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
JPWO2004069828A1 (ja) 2003-02-04 2006-05-25 三菱ウェルファーマ株式会社 ピペリジン化合物およびその医薬用途
US20050009817A1 (en) 2003-04-30 2005-01-13 Jennifer Savoy Substituted heteroaryls
CA2544377A1 (en) * 2003-11-03 2005-05-12 Schering Corporation Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
WO2005060947A2 (en) 2003-12-19 2005-07-07 Sri International Agonist and antagonist ligands of the nociceptin receptor
US20050250794A1 (en) 2003-12-19 2005-11-10 Andrew Napper Methods of treating a disorder
RU2006146985A (ru) 2004-05-28 2008-07-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы мускариновых рецепторов
PE20060598A1 (es) 2004-09-13 2006-08-21 Ono Pharmaceutical Co Derivado heterociclo conteniendo nitrogeno como antagonista de quimiocina ccr5
CA2581930A1 (en) 2004-09-27 2006-04-06 Jane Trepel Modulating mxa expression
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
WO2006130469A1 (en) 2005-05-27 2006-12-07 Oregon Health & Science University Stimulation of neurite outgrowth by small molecules
JP5209479B2 (ja) * 2005-09-30 2013-06-12 グラクソ グループ リミテッド Ｍ１受容体にて活性を有するベンゾイミダゾロン類
TW200813018A (en) 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
EP2197843B1 (en) 2011-12-28
AR071245A1 (es) 2010-06-09
PE20091090A1 (es) 2009-08-27
UY31334A1 (es) 2009-04-30
KR20100052528A (ko) 2010-05-19
CN101874020B (zh) 2012-11-07
MX2010002584A (es) 2010-03-26
AU2008299604A1 (en) 2009-03-19
TW200924766A (en) 2009-06-16
WO2009034380A1 (en) 2009-03-19
US8119661B2 (en) 2012-02-21
EP2197843A1 (en) 2010-06-23
US20090076078A1 (en) 2009-03-19
ES2377772T3 (es) 2012-03-30
CL2008002689A1 (es) 2009-11-27
CA2699286A1 (en) 2009-03-19
ATE539056T1 (de) 2012-01-15
RU2010110036A (ru) 2011-10-20
JP2010539151A (ja) 2010-12-16
CN101874020A (zh) 2010-10-27

Similar Documents

Publication Publication Date Title
BRPI0816331A2 (pt) Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto.
BRPI0818533A2 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI1006162A2 (pt) "composto,processo para preparar um composto,formulação farmacêutica,e uso de um composto".
BRPI0611956A2 (pt) composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto
BRPI0906475A2 (pt) Compostos, processso para a preparação de um composto, composição farmacêutica e uso de um composto
BRPI0813237A2 (pt) Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
BRPI0821676A2 (pt) Composto, composição farmacêutica, e, processo para a preparação dos compostos.
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0814611A2 (pt) Composição, processo para preparar uma composição, e, uso de uma composição
BRPI0908252A2 (pt) Processo para preparar um composto, e, uso de um composto
BRPI0910734A2 (pt) composto, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo.
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
BRPI0908738A2 (pt) composto, medicamento, uso de um composto, e, processo para preparar os compostos
BRPI0909691A2 (pt) Composto, método para preparar um composto, e, composição farmacêutica
BRPI0914927A2 (pt) composto, composição farmacêutica, métodos para inibir a função de fak e de tratamento de um câncer, uso de um composto, e, processo para preparar um composto
BRPI0811712A2 (pt) "composto, processo de preparação de um composto e composição farmacéutica".
BRPI0922714A2 (pt) composto, processo para preparar um compsoto, medicamento, uso de um composto, e, composição farmacêutica
BR112012016201A2 (pt) ''composto, processo para a preparação de um composto, composição farmacêutica e uso de um composto''
BRPI0911554A2 (pt) Microemulsão, processo para a preparação de uma microemulsão, e, uso da microemulsão.
BRPI0814821A2 (pt) Composto, composição farmacêutica, e, processo para preparar um composto
BRPI0815493A2 (pt) Composto, uso de um composto, composição faramcêutica, método para a terapia de dor, e, processo para preparar um composto.
BRPI0811275A2 (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, uso de composto, e, método para tratar doença
BRPI0813438A2 (pt) Processo para preparar um composto, uso de um composto, e, composto.
BRPI0612254A2 (pt) composto, formulação farmacêutica, combinação, e, processo para preparar um composto
BRPI0912163A2 (pt) Composto químico, processo para a produção de um composto, compsição química, e, uso de um composto químico.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]